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Running head: Morphometric analysis of explant CF lungs.  
Subject: 9.16 (Lung diseases, cystic fibrosis) 
Word count: 3500 (3500 max) 
At a glance commentary: 
Scientific knowledge on the subject: Chronic inflammation leads to bronchiectasis 
and mucus plugging in end-stage CF. 
What this study adds to the field: Using a combined approach with multidetector CT, 
microCT and histology, we quantified the extensive changes and remodeling in end-
stage CF lungs that start from airway generation 6 down to the level of the terminal 
bronchioles. 
This article has an Online Data Supplement, which is accessible from this issue’s table of 
content online at www.atsjournals.org 
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Abstract 
Rationale: After repeated cycles of lung infection and inflammation, patients with cystic 
fibrosis (CF) evolve to respiratory insufficiency. Although histology and imaging have 
provided descriptive information, a thorough morphometric analysis of end-stage CF lung 
disease is lacking.   
Objectives: To quantify the involvement of small and large airways in end-stage CF. 
Methods: Multidetector CT (MDCT) and microCT were applied to 11 air-inflated CF explant 
lungs and 7 control lungs to measure, count and describe the airway and parenchymal 
abnormalities in end-stage CF lungs. Selected abnormalities were further investigated with 
thin section histology.  
Measurements and main results: On MDCT, CF explant lungs showed an increased median 
(IQR) number (631 (511-710) vs 344 (277-349), p 0.003) and size of visible airways 
(cumulative airway diameter 217 (209-250) cm vs 91 (80-105) cm, p < 0.001) compared to 
controls. Airway obstruction was seen, starting from generation 6 and increasing to 40-50% 
of airways from generation 9 onwards.  MicroCT showed that the total number of terminal 
bronchioles was decreased (2.9 (2.6-4.4)/ml vs 5.3 (4.8-5.7)/ml, p<0.001); 49% were 
obstructed and the cross sectional area of the open terminal bronchioles was reduced (0.093 
(0.084-0.123) vs 0.179 (0.140-0.196) mm², p<0.001). On microCT, 41% of the obstructed 
airways re-opened more distally. This remodeling was confirmed on histological analysis. 
Parenchymal changes were also seen, mostly in a patchy and peribronchiolar distribution.  
Conclusions: Extensive changes of dilatation and obstruction in nearly all airway generations 
were observed in end-stage CF lung disease.  
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List of abbreviations 
CF  cystic fibrosis 
CF-CT  cystic fibrosis chest tomography 
IQR  interquartile range 
FEV1   forced expiratory volume in 1 second  
FEF25-75  forced expiratory flow between 25 and 75% of the expired volume 
FEF75   forced expiratory flow at 75% of the expired volume 
FVC   forced vital capacity 
Lm  mean linear intercept 
MDCT  multidetector CT 
RV   residual volume 
SALD  severe advanced lung disease  
T%  tissue percentage 
TB  terminal bronchioles 
TGV   total gas volume 
TLC   total lung capacity  
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VC   vital capacity 
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Introduction  
Cystic fibrosis (CF) is a life-shortening disease with more than 90% of subjects dying from 
respiratory insufficiency (1).  
The origins of CF lung disease are still not entirely understood. Abnormal mucus composition 
and secretion, defective mucociliary transport, reduced pH, impaired bacterial killing and 
excessive inflammatory responses probably all contribute to the initiation of lung disease (2). 
These early CF events quickly lead to structural lung damage, even in young children and in 
the absence of obvious clinical signs of lung disease (3). In the later disease stages, 
successive pulmonary exacerbations lead to progressive airway obstruction and increasingly 
severe structural lung damage with mucus impaction, bronchiectasis, atelectasis, 
hyperinflation and mosaic perfusion as main features (4, 5).    
Thanks to several registry studies, the natural course of CF lung disease has been well 
described at the clinical, bacteriological and lung function level. Detailed information on lung 
remodeling is, however, lacking: imaging studies only provide indirect information about 
lung structure and lung histology samples are not easily obtained. An autopsy series of 82 
children who died before the 1970s, describes disease progression: bronchitis, glandular 
hypertrophy, mucus plugging and bronchopneumonia are seen at all ages, but bronchiectasis 
is mainly seen in older children (6). A detailed histology/radiology correlation of 8 CF lungs 
from young adults who died in the 1970s, highlights focal areas of peribronchial pneumonia 
with necrosis and abscess formation, mostly surrounded by intact lung parenchyma and 
dilatation of central and peripheral airways (7). Some studies have examined the size and 
number of airways smaller than 2 mm in end-stage CF lungs (8-11). However, the results are 
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not consistent, likely due to a difference in methods between studies and the lack of control 
lungs.  
High resolution CT has been used to quantify histologically described abnormalities. 
However, the resolution of current in vivo imaging limits the study of the small airways. 
Thus, although histology and imaging provide descriptive information on lung structure in 
CF, a thorough morphometric analysis of the CF lung is lacking. Recently, the development of 
microCT allows high resolution imaging and three dimensional viewing of the peripheral 
airways down to the level of the terminal bronchioles and alveoli (12, 13). A detailed 
description of CF lung pathology is indeed crucial to develop optimal treatment strategies. 
Our aim was therefore to combine multidetector CT (MDCT) and microCT to measure, count 
and describe the airway and parenchymal abnormalities in end-stage CF lungs. In addition, 
abnormalities detected were further explored and correlated with histology sections.  
Some of the results of these studies have been previously reported in the form of abstracts 
(14-20). 
Methods  
Patients 
We examined the left lungs, explanted from 11 patients with CF who underwent lung 
transplantation at the University Hospital of Gasthuisberg Leuven (Belgium) between June 
2010 and July 2012. Prior to surgery, informed consent to analyze these lungs had been 
obtained from all patients. Seven non-used donor lungs were used as controls. Reasons why 
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donor lungs were not used for lung transplants are described in Online Supplement E1. The 
local hospital’s ethical committee approved this study (ML6385).  
Baseline CF patient characteristics were retrieved from the patient files. Last available results 
for spirometry and plethysmography were included and expressed as % predicted (21, 22). 
Pre-operative chest CT scans were evaluated in random order with CF-CT score, a validated 
upgraded version of the Brody-II score, (23, 24) and with SALD score (25) (Online 
Supplements E1).  
Preparation of lungs for MDCT and microCT 
The lungs were air-inflated to total lung capacity (TLC), frozen solid in the fumes of liquid 
nitrogen, and scanned with MDCT, according to a previously reported protocol (12, 13) 
(more detailed descriptions of the material and methods can be found in Online 
supplements E1). After MDCT scanning, the lungs were cut in 2 cm thick slices. From each 
slice, cores with a diameter of 1.4 cm were excised and processed for microCT scanning.  
MDCT scan analysis 
The airway bifurcations were counted manually by scrolling through the MDCT scan and 
numbered from proximal to distal. The main stem bronchus was considered generation 1 
and each subsequent bifurcation was counted as a new airway generation until the visibility 
of more distal generations was limited by the resolution of the MDCT (0.6 mm). The number 
of airways was calculated from the number of bifurcations. The diameter of each airway 
segment was measured at the level of the most pronounced dilatation, not to underestimate 
bronchiectasis. Cumulative airway diameter was calculated as the sum of all airway 
diameters per generation, to quantify the extent and severity of bronchiectasis. Airway 
Page 8 of 47 AJRCCM Articles in Press. Published on 09-November-2015 as 10.1164/rccm.201507-1281OC 
 Copyright © 2015 by the American Thoracic Society 
9 
 
obstructions were defined as complete loss of the airway lumen, with no visible re-opening 
of the lumen downstream of the obstruction (Figure 1).  
MicroCT scan analysis 
The microCT resolution of 16.8 µm allowed to count and measure terminal bronchioles (TB) 
present in a lung core with a known volume. The TB represent the last generation of airways 
with a circumferential wall, before alveolar buds become visible. They represent the 
entrance to the pulmonary acinus and the point of transition from convection to diffusion of 
gasses in the lung. The number of TB/mL tissue were counted and the diameter/cross-
sectional area of each TB was measured at their most distal point before evolution to 
respiratory bronchioles.  
The parenchyma of lung cores of CF was compared to that of control lungs and was 
described in a qualitative way. The mean linear intercept (Lm), the mean distance between 
alveolar walls and thus a measure of emphysema, and parenchymal tissue volume (T%), a 
measure of fibrosis, were quantified. 
The patency of TB and more proximal airways present in the microCT core was explored by 
following their path through the core. 
Histology  
Selected cores with specific features of interest on microCT (e.g. obstruction) were 
processed for histological analysis (Online Supplement E1). 
Statistics 
Because of low numbers, non-parametric statistics were used. Results were expressed as 
median (IQR).  
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Comparison between groups was performed by Mann Whitney test for continuous variables 
or Fisher’s exact test for categorical variables. Correlations between parameters were 
assessed with Spearman correlation coefficients. All statistical analyses were performed with 
IBM SPSS Statistics 21.0. A p-value <0.05 was considered statistically significant.  
MB and BB were trained to perform lung morphometric analysis and their results were 
validated against experienced readers (SEV and JM). 
Results 
Patient characteristics are reported in Table 1. Patients with CF were significantly younger (p 
< 0.001), shorter (p = 0.008) and lighter (p < 0.001) than control subjects. Pre-transplant lung 
function in CF showed very severe airway obstruction (low FEV1 and FEV1/FVC) and air 
trapping as indicated by high residual volume (RV). CT analysis showed that CF lungs had 
smaller volumes than the control lungs (p = 0.004), but were heavier (p = 0.015) and thus 
had a higher density (p < 0.001) (Table 2).  
When comparing airway diameters between CF and control, the shorter stature and smaller 
lung volume could be possible confounders. Therefore, in MDCT analysis, the airway 
diameters of CF and control lungs are reported as corrected airway diameter (airway 
diameter/left lung volume).  
The results for CF-CT and ex vivo and in vivo SALD scores of the left lung are shown in Table 
Online Supplement E2.  
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MDCT 
In CF, the number of visible airway bifurcations was increased compared to controls (631 
(511–710) vs 344 (277–349),  p = 0.003), there was a significant increase in corrected airway 
diameter per airway generation  (p = 0.01) (Table 2 and Figure 2a and 2b) and in cumulative 
airway diameter per lung (217 cm (168–306) vs 91 cm (80–105), p < 0.001) (Figure 2c). 
Compared to control lungs, the number of visible airways was increased from airway 
generation 9 on and the diameter was increased from generation 6 on. A median of 35% 
(26–43) of airways per lung was obstructed, with obstructions starting from airway 
generation 6 and increasing to 50% in the more peripheral airways (Figure 2d). In control 
lungs, obstruction of airways was not observed.  
The number of visible large (≥2 mm) and small airways (< 2 mm) was increased. A total of 
340 (184–413) large airways per lung were seen in CF versus 116 (67-124) in controls (p 
<0.001) and 811 (539–1134) small airways per lung in CF versus 562 (425–585) in controls (p 
= 0.055) (Figure Online supplement E3).  
In control lungs, there was no different number of airways counted in the upper (134 (111-
235) versus the lower lobe (166 (114-211) (p = 0.81). However, in CF, the total number of 
visible airways was lower in the upper lobe compared to the lower lobe (218 (132-265) vs 
426 (246-578), p = 0.019). The total cumulative airway diameter did not differ between 
upper and lower lobe in controls (38.6 cm (28.1-41.6) vs 51.9 cm (30.4-64.9), p = 0.32) nor in 
CF (71.6 cm (62.3-130.9) vs 109.8 cm (85.4-209.5), p = 0.12). The percentage of obstructed 
airways was similar in upper and lower CF lobes (38.1% (30.2-44.4) vs 33.3% (26.6-40.4), p = 
0.40). 
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In CF lungs, there was a positive correlation between the number of airway generations and 
the cumulative airway diameter (r 0.75, p = 0.008) and an inverse correlation with the 
percentage of obstructed airways (r -0.66, p = 0.026).  
MicroCT and histology 
Approximately 9 cores per lung were analyzed with microCT, resulting in a total of 67 cores 
from control and 100 from CF lungs. It must be noted that the very peripheral lung regions 
may be underrepresented, as explained in Online Supplements E1. 
The median number of visible (open or obstructed) TB/ml was significantly reduced in CF 
versus control cores (2.9/ml, (2.6-4.4) vs 5.3/ml (4.8-5.7), p < 0.001) (Table 2). The median 
TB diameter and their median cross-sectional area were also diminished (217 µm (209-250) 
vs 349 µm (346-405), p < 0.001 and 0.093 mm² (0.084-0.123) vs 0.179 mm² (0.140-0.196), p 
< 0.001). Obstruction of TB was not seen in control cores. In CF, only 49% of the TB remained 
open over their entire course; 59% of obstructed TB were completely obstructed, in 41% the 
lumen reopened downstream of the obstruction before leading into an open respiratory 
bronchiole (Figure 3). The number of open TB/ml was thus significantly reduced in CF versus 
controls (2.6/ml (1.5-3.2) vs 5.3/ml (4.8-5.7), p < 0.001).  
In the 100 CF cores, 466 airways with lumen obstruction were identified. In 389 (83%), the 
lumen remained obstructed and the airway appeared to disappear downstream of the 
obstruction (Video Online Supplement E4). In the remaining 77 airways (17%), the airway 
lumen restored downstream of the obstruction, albeit with a significantly decreased 
diameter (493 µm (351-923) upstream vs. 188 µm (122-255) downstream of the obstruction, 
p < 0.0001). The median length of the obstructed segments was 1.81 mm (1.357-2.77). A 
representative lesion is shown in Online Supplement E5. Matched histological examination 
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of this lesion (Figure 4) showed airway wall thickening and mucus plugging, recognizable by 
purple, intraluminal threads. When following this airway downstream on microCT and 
matched histological slices, we observed airway branching, decreasing of the lumen size until 
it disappeared. However, further downstream, this airway re-opened with a delineated 
airway wall and lumen (3D reconstruction video Online Supplement E6). Detailed staining of 
another obstructive lesion showed neo-angiogenesis in the destructed airway wall and 
replacement of the obstructed lumen by granulation tissue, characterized by the presence of 
thin type III collagen fibers (Online supplement E7). 
CF cores had an increased tissue% versus controls (42%, (26-46) vs 28% (26-29), p < 0.001). 
The Lm measurements of the analyzed cores did not differ between CF and controls (239 
(222-256) in CF versus 230 (212-239) in controls, p = 0.29).  
On microCT, the parenchyma had a heterogeneous appearance with sudden transitions 
between normal and abnormal regions, often delineated by thickened septa. Parenchymal 
lesions were mainly centered around the airways: e.g. fibrotic emphysema around 
bronchiectatic lesions; zones of scarring and atelectasis around bronchioli (Figure 5).  
Correlations between MDCT/microCT and spirometry/CT scores 
The total number of airway obstructions on MDCT correlated with the RV (r 0.65, p = 0.043), 
but not with other lung function parameters. There was no correlation between the number 
of open TB/ml and any lung function parameter.  
The total cumulative airway diameter correlated significantly with the CF-CT score and the 
bronchiectasis subscore (r 0.76, p = 0.007 and r 0.86, p = 0.001 respectively). The total 
cumulative airway diameter also correlated with the SALD ex vivo subscores 
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‘infection/inflammation’ (r 0.76, p = 0.007) and the subscore ‘low attenuation’ (r -0.66, p = 
0.026). The number of visible airway generations and the percentage of airway obstructions 
did not correlate with CT scores.  
Discussion 
We conducted a thorough morphometric analysis of end-stage CF lungs and showed 
extensive changes in the conducting airways as well as in the TB, situated in the transition 
zone from convective flow to diffusion. In the conducting airways, as observed with MDCT, 
mainly from airway generation 6 on and thus from the level of bronchioli, dilatation and 
obstruction of up to 50% of airways per generation was seen. Due to a widespread 
dilatation, more airways were visible above the threshold of 0.6 mm (resolution of HRCT) 
and the number of visible airways increased. There is a wide variability between patients in 
the findings on HRCT, reflecting predominance of large bronchiectasis with pronounced 
destruction in some patients, and hyperinflation with small airways obstruction in other 
patients. MicroCT allowed the study of the TB, where dramatic reduction of the number of 
TB and especially open TB, was seen. The gateways to the lung acini where oxygenation 
takes place was more than halved compared to non-used donor lungs.  
We have now quantitatively shown that CF affects the peripheral airways, as was already 
previously suggested by indirect findings on spirometry, multiple breath washout and 
imaging (26). This process starts early in CF lung disease since the increased visibility of 
airways on chest CT, possibly induced by their dilatation, has also been confirmed in children 
with CF and tends to increase with age (27, 28, 29). Together, this information points 
towards the need for better treatment of CF small airway disease.  
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These changes in number and size of TB, the gateways to the lung acini where oxygenation 
takes place, must have extensive consequences for normal ventilation and oxygenation. 
Indeed, normal airway branching and airway size are strictly regulated so that air flow 
steadily slows down by a progressive increase in total airway surface area. The orderly 
progression of airway diameters assures convective airflow throughout the bronchial tree 
with minimal resistance and dead space volume following the laws of Hess and Murray (30). 
In this way, the flow velocity of the air in the distal bronchial tree will match the diffusion 
velocity in acinar airways (30, 31). Likewise, the exact size and design of the acinus is critical 
to allow for optimal oxygenation at rest and during exercise by gas diffusion (32). In CF, the 
lung damage mainly occurs in the airways, with the interstitium and alveoli appearing better 
preserved. Hence, one could speak of a dissociation between the defective ventilation and 
diffusion through the airways and the almost normal gas exchange membrane. In theory, gas 
exchange capacity is thus preserved in the distal periphery of the lung. Again, more efficient 
treatment of small airway disease has the potential to greatly improve outcome in CF.  
We have also shown that many airways that are obstructed, remain obstructed over their 
entire course or disappear under the detection limit of MDCT, while others re-open 
following an obstruction. Given the widespread airway obstruction while areas of atelectasis 
are remarkably limited, extensive collateral ventilation must go on in the CF lungs, possibly 
via interbronchiolar pathways of Martin, bronchiole-alveolar communications of Lambert or 
the interalveolar pores of Kohn (33). Although certainly less effective than ventilation 
through airways and less important in healthy lungs, pulmonary interdependence is likely 
the main driver of collateral ventilation in the presence of airway obstruction and especially 
when areas of the lungs have preserved ventilation. This explains why hypoxia is only seen in 
terminal CF, despite very severe flow obstruction. These data also agree with previous 
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findings of extensive obstruction and air trapping on chest CT of patients with end stage CF 
lung disease (25). 
Staining for collagen further confirms the presence of newly formed collagen fibers and 
neovascularisation in these areas of obstruction, as present in granulation tissue. The 
mechanism of these obstructions is not known but resembles our previous findings in lungs 
with bronchiolitis obliterans syndrome after lung transplantation, where airways more 
proximal to the terminal bronchioles were obstructed, re-opened down-stream giving rise to 
a normal number of terminal bronchioles (13). In CF, this phenomenon is seen down to the 
TB level.  
Our morphometric findings in control lungs are in agreement with the previously suggested 
TB size (490 µm), alveolar size (162 µm) and number of branching generations (varying from 
18 to 30) (30). The control and CF lungs were well-inflated before freezing and therefore the 
measured dimensions should reflect in vivo measurements. The similar findings on CT 
imaging using SALD score in vivo and later ex vivo also validate the complex technique of 
lung processing. Likewise, our findings in CF are in agreement with previous histology 
information of mainly peribronchial disease and the patchy distribution throughout the lung 
(7, 9, 34-36). Even with 40 years between the obtained samples, and with a vastly different 
treatment regimen, these main features are still prominently present.  
The findings of our study are of high clinical relevance for the treatment of CF lung disease. 
The maintenance treatment of chronic CF lung infection and airway obstruction aims to 
improve airway clearance through inhalation of mucolytics, airway hydrators or dornase 
alpha as well as chest physiotherapy while combatting airway infection with inhaled 
antibiotics (37, 38). These drugs, however, are unlikely to reach the peripheral airway 
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generations where airway obstruction is most prominent, while chest physiotherapy 
techniques have also little impact beyond the more central airways. Novel therapies already 
attempt to target the more peripheral airways by improving the deposition of nebulized 
drugs and inhaled dry powders (39), and prevention of airway destruction by dampening the 
local inflammation is another treatment goal (40). Targeting this peripheral airway disease in 
an early stage to prevent destruction seems appropriate. 
MDCT and microCT have also been used to study other obstructive lung diseases: major 
differences in site and nature of airway obstruction exist between chronic obstructive 
pulmonary disease (COPD) (12) and rejection after lung transplant (13). In COPD, the number 
of visible airways is decreased from airway generation 6 on; in chronic rejection these are 
not decreased but obstructed airways appeared with decreasing airway diameter. Only in CF 
an increase of visible airways was determined, but the proportion of obstructed airways 
increased from generation 6 to generation 9 and then remained constant around 40-50% of 
visible airways. MicroCT analysis of COPD lungs demonstrated a reduction of 80% in number 
of TB and of cross sectional area of TB; lung rejection was characterized by a normal number 
and size of TB. In CF, the number of TB per ml and their cross sectional area decreased 
around 50%, confirming that CF is a small airways disease, encompassing the TB and 
continuing up to generation 6.  
Several drawbacks of the study can be identified. The study group is small due to time 
consuming and labor intensive analysis, and a challenging recruitment of control lungs. 
Manual counting of airways on HRCT is time-consuming, but gives much more information 
on airway generations compared to a general impression of the number of airways, obtained 
by automated airway counting, as described by de Boer et al. (27). The technique of microCT 
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is promising, but due to very high irradiation doses not applicable in vivo. We thus cannot 
obtain information on earlier stages of lung disease as its use is limited to explant or cadaver 
lungs. Relatively small parts of the lungs were analyzed by microCT and the very peripheral 
lung regions may be underrepresented. However, most previous studies only used a single 
biopsy per lung, while we studied around 9 cores spread throughout each lung. However we 
may have missed other types of lesions, especially in the lung periphery adjacent to the 
pleura.  
Age, weight and height differed between CF and controls and this hampered comparing 
airway dimensions. Yet the differences between controls and CF are so clear that including 
more samples is unlikely to change our findings. There is a gap in evaluation of airway 
generations with MDCT (reliable up to 600 µm visibility) and microCT (with resolution of 16.8 
µm); only the latter allows a detailed view of TB and further downstream to the level of the 
alveoli. An adult lung is too large to fit entirely in the microCT scan. By exploring all the 
airways in the microcores, no matter what generation they were, we tried to overcome that 
problem and concluded that obstruction and destruction were present in all airway 
generations.   
In conclusion, in end-stage CF lung disease, we have identified extensive airway dilatation 
and obstruction in all airway generations from generation 6 on with an enormous reduction 
in the number and size of TB, the entry to the gas exchange unit of the lung. This accounts 
for the difficulty in ventilation and oxygenation present in end stage lung disease. Further 
study is needed to examine how these lesions arise during the course of the disease and 
how therapy can be directed to prevent these obstructions. 
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Figure legends 
Figure 1: Airway obstructions as seen on MDCT 
1a: Obstructions in large airways in transversal MDCT section. A large saccular bronchiectatic airway 
with a 0.5 cm diameter (A) is partially filled with mucus (arrow) and is followed downstream (B-C). 
After branching (D, arrowhead), one bronchus suddenly narrows (G, arrow), becomes obstructed (H, 
arrow) and disappears (I). The other bronchus remains open (G-I), branches again (J, arrowhead), and 
once more one branch becomes obstructed and disappears (K-L, arrow), while the other branch 
remains open.  
1b: Obstructions in distal airways in longitudinal sections. The lumen of a small, peripheral airway can 
clearly be discerned (arrow, M-N). However one section downstream shows the lumen gets filled (O), 
resulting in a closed lumen (arrowhead) which is not discernible any more with MDCT (P, 
arrowhead). 
Figure 2: Results of MDCT scan analysis 
2a: Airway diameter per airway generation in control and CF lungs. Data are shown as median and 
95% CI. The median number of visible airways per generation is presented in the legend of the graph 
for CF and control lungs.  
2b: Corrected airway diameter per airway generation in control and CF lungs. Data are shown as 
median and 95% CI. The median number of visible airways per generation is presented in the legend 
of the graph for CF and control lungs.  
2c: The cumulative airway diameter (not corrected for lung volume) per generation in CF and control 
lungs. Data are shown as median and 95% CI. The median number of visible airways per generation is 
presented in the legend of the graph for CF and control lungs.  
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2d: The number of visible airways in control lungs and in CF lungs as seen with MDCT. More airways 
are visible in CF lungs, from generation 9 on. In control lungs there are no obstructed airways. In CF 
lungs, patent as well as obstructed airways are seen.  
Figure 3: Terminal bronchiole on microCT imaging 
Obstruction at the level of a terminal bronchiole. Panel A shows an overview of a lesion, starting 
proximally from a dilated airway (*) that becomes obstructed with mucus (arrowhead). The lumen 
reopens more distally at the level of the terminal bronchiole (TB), before giving rise to the respiratory 
bronchioles (RB). Panels B to I show transverse views from proximal to distal along this same airway 
track to unequivocally demonstrate airway obstruction and reopening distally. Intermittent 
reappearing of the airway lumen in panel D.  
Figure 4: Validation of airway abnormalities on microCT by histology of same 
section  
A bronchiectatic lesion (red arrowhead), with a diameter much larger than the accompanying vessel, 
is shown (blue arrow) (a). The lumen gets partially filled with mucus, while the lumen is getting 
smaller and smaller, resulting in an airway with no discernible lumen any longer. (b-d), Surprisingly, 
more distally from this completely occluded airway, we see that the airway bifurcates (g) with one 
branch re-opening with a smaller airway lumen (h), while the other remains obstructed (green 
arrowhead). 
Figure 5: Parenchymal lesions as seen on microCT 
 (A) the thickened septum separates a zone with increased density of the interstitium from a zone 
with normal looking parenchyma and alveoli (N).  
(B) peribronchiolar scarring with and dilatated emphysematous alveoli (*)  
(C) zone of scarring and atelectasis centered around a bronchiolus (arrowhead) 
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Tables  
Table 1: Baseline characteristics of controls and patients with CF  
   Controls CF p-value (Mann-
Whitney or Fisher 
exact test) 
Number of subjects 7 11  
Sex ratio M/F 5/2 4/7 0.34 
Age (years) 53 (43 -66) 22 (21 – 28) < 0.001* 
Height (cm) 175 (170 – 180) 160 (153 – 172) 0.008* 
Weight (kg) 80 (65 – 85) 45 (41 – 57) < 0.001* 
Pulmonary Function 
% pred, median (IQR) 
    
S
p
ir
o
m
e
tr
y 
FVC  -  44 (35-53)  
FEV1  - 24 (18-29)  
FEV1/FVC  - 52 (47-57)  
FEF25-75  7 (5-8)  
FEF75  7 (6-7)  
P
le
th
y
sm
o
g
ra
p
h
y
 
TLC  - 95 (81-102)  
VC  - 54 (36-67)  
RV  - 196 (167-257)  
TGV  - 123 (115-149)  
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Legend: results are given as N or median (IQR). Abbreviations: IQR interquartile range; FVC 
forced vital capacity; FEV1 forced expiratory volume in 1 second; FEF25-75 forced expiratory 
flow between 25 and 75% of the expired volume; FEF75 forced expiratory flow at 75% of the 
expired volume; TLC total lung capacity; VC vital capacity; RV residual volume; TGV total gas 
volume; * statistically significant  
Table 2: Results of ex vivo MDCT and microCT analysis 
Ex vivo MDCT 
measurements (left lung) 
Controls CF p-value (Mann-
Whitney) 
Lung volume (L) 3.21 (2.91 – 3.63) 2.22 (1.96 – 2.46) 0.004* 
Lung mass (g) 433 (399 – 474) 623 (493 – 784) 0.015* 
Lung density (g/L) 137 (124 – 150) 241 (236 – 334) < 0.001* 
Cumulative airway 
diameter (cm) 91 (80-105) 217 (209-250) 
< 0.001* 
Airway bifurcations (n) 344 (277-349) 631 (511-710) 0.003* 
Airway obstructions (%) - 35 (28-43)  
Ex vivo microCT 
measurements   
 
Number of visible TB (n/ml) 5.3 (4.8-5.7) 2.9(2.6-4.4) < 0.001* 
Number open TB (n/ml) 5.3 (4.8-5.7) 2.6 (1.5-3.2) < 0.001* 
Diameter of TB (µm) 349 (346-405) 217 (209-250) < 0.001* 
Cross-sectional area of TB 
(mm²) 
0.179 (0.140-
0.196) 
0.093 (0.084-0.123) < 0.001* 
Lm 230 (212-239) 239 (222-256) 0.285 
Tissue% 28 (26-29) 42 (36-46) < 0.001 
 
Legend:  
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Parameters are expressed as median and interquartile range. The ex vivo microCT parameters are 
based on the measurements in the selected cores. Because there may be underrepresentation of the 
peripheral lung regions, no assumptions on the whole lung can be made. 
Abbreviations: MDCT multidetector CT ; TB terminal bronchiole; Lm mean linear intercept, * 
statistically significant by Mann Whitney U test. 
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Cindy Mai
4
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4
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5
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ONLINE DATA SUPPLEMENT 
Online Supplement E1: Methods 
Patient material and information 
Reasons for ineligibility of the control lungs as donor lungs consisted of: ‘receptor could not 
be allocated within timeframe’ (n=3), ‘receptor died before the lungs could be engrafted’ 
(n=1), ‘renal tumor was detected at the moment of prelevation’ (n=1), ‘persistent 
embolization’ (n=1) and ‘low donor paO2’ (n=1). Organs were obtained at the University 
Hospital Gasthuisberg (n=4) and from the Organ Donor Program of the Gift of Life 
organization in Philadelphia (n=3). Informed consent was obtained from the donors’ next of 
kin or was presumed according to the Belgian law that allows the use of organs for donation 
or research, unless a person explicitly decides to ‘opt out’. 
CT scoring 
CF-CT scoring was performed by a validated scorer, MB (validation through on-line training 
module of corelab LungAnalysis Rotterdam, the Netherlands) (1). Abnormalities were 
evaluated according to Fleischner society nomenclature (2). Every lobe was scored for 
bronchiectasis, airway wall thickening, mucous plugging, parenchym abnormalities on 
inspiratory images and air trapping on expiratory images (if available). More specifically, 
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bronchiectasis was defined as a bronchus lumen diameter greater than the accompanying 
pulmonary artery outer diameter, lack of tapering of the bronchus or bronchi visible in the 
outer centimeter of the lung. Airway wall thickening was defined as a wall thickness to artery 
diameter ratio >0.2, this was assessed subjectively. Each abnormality was scored per lobe 
and the extent involved with the abnormality was estimated as less than one-third, between 
one-third and two-thirds, and more than two-thirds of the lobar volume, scored from 0 to 3. 
The subscores were calculated with correction for the extent of the observed abnormalities. 
The total CF-CT score per lobe is the sum of all the subscores, the total CF-CT score is the 
sum of the scores for all 6 lobes. If a lobe showed complete atelectasis, only maximum score 
(3) for consolidation could be counted for that lobe. Bronchiectasis, airway wall thickening 
and mucus plugging should be scored as 0 for that lobe. A score for the left lung was 
obtained and expressed as % of the maximum score for that lung.  
SALD scores were calculated by the Lung Analysis Core Lab (Erasmus MC – Sophia, 
Rotterdam, The Netherlands) using sophisticated image analysis software (3, 4). Scoring of 
the CT scans was performed according to the standard operating procedure (SOP) 3.0 of ‘The 
SALD Score’. A 10 x 10 mm grid was projected over each slice and each grid cell was 
manually assigned to one of four components, using different colors. Four abnormalities 
were scored in increasing order of priority as listed below. The number of grid elements per 
color (abnormality) was counted and expressed as % of the total number of colored grid elements for 
all slices.  The total score is always 100%. 
1. Infection/inflammation (inf/infl) (red): % of total volume measured, min 10 
slices/CTscan scored. All grid cells containing (parts of) abnormalities: bronchiectasis, 
airway wall thickening, mucus, consolidation. 
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2. Regions of low attenuation (LAR) (blue): % of total volume measured, min 10 
slices/CTscan scored. All grid cells containing distinctive low attenuation that are not 
containing diseased lung tissue (infection/inflammation, bullae/cysts) and has more 
than 50% trapped air per grid cell. 
3. Bullae/cysts (Bul/cys) (yellow): % of total volume measured, min 10 slices/CTscan 
scored. All lung tissue containing (parts of) bullae or cysts with no connection to the 
bronchial tree. 
4. Normal/hyperperfusion (normal) (green): % of total volume measured, min 10 
slices/CTscan scored. All grid cells containing (parts of) normal lung tissue (>50%/grid 
cell).  
It was shown previously that scoring one slice every 30 mm was sufficient to compute 
reproducible and accurate scores (4).  
SALD scores were applied on in vivo HRCT scans before transplantation and on ex vivo MDCT 
scans of the explanted lungs. 
Preparation of lungs for MDCT, microCT and histology 
The lungs were prepared in frozen state, according to a previously reported protocol (5, 6). 
After excision of the left lung, the main stem bronchus was cannulated, the lung was inflated 
to total lung capacity by applying a constant pressure of 30 cm H2O. The lung volume was 
then maintained but the distending pressure was slightly diminished to a pressure of 10 cm 
H2O, to prevent dissection of air into the interstitial space. The lungs were then frozen in 
liquid nitrogen vapor and stored at -80°C. The frozen lungs were scanned with MDCT 
(Siemens SOMATOM definition flash, 120 kV, 110 mA∙s, reconstructed at 0.6 mm in-plane 
resolution, and a slice thickness of 1 mm, kernel B60 sharp).   
Page 39 of 47  AJRCCM Articles in Press. Published on 09-November-2015 as 10.1164/rccm.201507-1281OC 
 Copyright © 2015 by the American Thoracic Society 
 4
After MDCT scanning, the lungs were cut from apex to basis with a band saw in 2 cm thick 
slices. From each slice, cores with a diameter of 1.4 cm were excised (up to 12 cores per slice 
from central and more peripheral lung regions were included). The way we obtained the cores 
from the slices does not meet ATS standards for Quantitative Assessment of lung structure (7) and 
may be a drawback of the study. Cores completely filled with lung tissue were extracted from the 
slices and only a few overlapped the lung border and the pleura. Because of the cylindrical shape of 
the cores, the very peripheral regions adjacent to the pleura may be insufficiently represented, and 
therefore we cannot make assumptions on the whole lung. We believe that this sampling bias will 
not confound the study results, as the differences between CF and control are so pronounced and 
since CF and control lungs were processed in the same way.  
Per slice one core was randomly selected, so that approximately 10 cores per lung were processed 
for microCT scanning, using a fixation and dehydration protocol. 
The cores were fixed overnight in a 1% solution of glutaraldehyde in pure acetone, 
subsequently dehydrated by applying an increasing ethanol concentration and dried by 
chemical dehydration with hexamethyldisilazane (8). A SkyScan 1172 microCT device 
(SkyScan, Kontich, Belgium) was used to scan the cores with a resolution of 8.39 µm (40 kV, 
250 mA).  
MDCT and microCT images were analyzed using OsiriX 4.1 software (Pixmeo, Geneva, 
Switzerland).  
Lung mass, volume and density were measured based on the density of the pixels with 
custom-made software, based on MDCT measurements. 
MicroCT images were taken at regularly spaced intervals of 839 μm within the same core for 
measurements of mean linear intercept (Lm), which is the mean distance between alveolar 
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walls and the percentage of parenchymal tissue volume (T%). Quantification was done using 
Adobe Photoshop CS5 Extended v12.0.1 (Adobe, San Jose, California, USA) to manually 
separate blood vessels and airways and threshold parenchymal issues from air. Lm and T% 
were then measured using a previously validated grid of test lines and a custom macro 
(Image pro plus 6.1 software; Media Cybernetics, Rockville, USA). Lm and T% are known to 
correlate well with histological analysis of alveolar size and tissue density (6). 
Cores with specific features were processed for histological analysis: the samples were 
rehydrated in 4% paraformaldehyde for 3 days, embedded in paraffin, sliced in 8 µm 
sections and stained with haematoxylin-eosin (H&E) staining or picrosirius red staining, to 
visualize collagen fibers. Sections were examined using an Olympus BX61 light microscope 
(Olympus, Aartselaar, Belgium) and accompanying software. 
Table Online Supplement E2 
Results of in vivo HRCT and microCT analysis 
  CF 
In vivo HRCT CF-CT score (left lung)  
CF-CT score (%) 34.3 (31.6 – 37.9) 
CF-CT bronchiectasis subscore (%) 37 (31-46)  
In vivo SALD score 
 
Inflammation/infection (%) 51 (39-62) 
Low attenuation (%) 42 (24-47) 
Normal (%) 14 (11-21) 
Ex vivo SALD scores (left lung) 
 
Inflammation/infection 
48 (44-58) 
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Low attenuation 
40 (31-42) 
Normal (%) 
10 (8-15) 
 
Legend:  
Parameters are expressed as median and interquartile range. The results for in vivo and ex vivo SALD 
scores were almost identical.  
Abbreviations: HRCT high resolution CT. 
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Figure Online Supplement E3 
Visible airways on MDCT per airway generation and airway size in control lungs and CF lungs.   
A. Large airways (≥ 2 mm) B. small airways (< 2 mm)  
Legend: In CF there is an increase in visible large airways on MDCT, and even more so visible small 
airways on MDCT compared to control lungs.   
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A 
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Online supplement E4: 
MicroCT video of an airway that becomes obstructed with mucus and completely disappears after 
obstruction. 
Online supplement E5: 
MicroCT video of an airway that shows obstruction of the lumen, but restoration downstream of the 
obstruction.  
Online Supplement E6: 
3D reconstruction of airway that is obstructed but reopens with restoration of the lumen more 
distally from the obstruction. 
B 
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Figure online supplement E7: 
Large airway with partial mucus obstruction. Panel A, B, C: microCT images; panel D, E, F: histology of 
same sections (hematoxylin and eosin stain); panel G, H: histology:  picrosirius red stain for collagen 
fibers. At the branching point, the lumen of the left branch (L) remains open, the right branch is 
completely obstructed with mucus (M). Newly formed small blood vessels are recognized in the 
airway wall (arrow head). Picrosirius red staining shows green collagen fibers (*) in this obstructed 
airway, indicating the recent formation of thin type III collagen fibers, present in granulation tissue. 
BV: blood vessel 
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